glycylprolyl β-naphthylamidase activity in human serum

Hino, Masao; Nagatsu, Toshiharu; Kakumu, Shinichi; Okuyama, Sumihiko; Yoshii, Yuri; Nagatsu, Ikuko

doi:10.1016/0009-8981(75)90273-9

Cited by 72 publications

(29 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To our knowledge, only one study reported a decrease of protein sCD26 (but to a lesser extent than ours) in oral cancer patients (Mogi et al, 1986), although the authors measured a higher quantity of protein than we by using the commercial kit. In addition, some of our data are not in accordance with published measurements of DPP-IV enzymatic activities in some diseases such as GC (lower levels than in normal subjects) (Hino et al, 1975), or in some patients of the BCC group (Fujita et al, 1977). As at least one different serum protein accounting for the DPP-IV activity (DukeCohan et al, 1996) as well as new discovered cellular proteins with DPP-IV activity (Pangalos et al, 1999;Underwood et al, 1999) have been described, these facts should encourage more complete studies at the protein level on different pathologies.…”

Section: Discussioncontrasting

confidence: 99%

“…There were no significant differences between the two sex-and age-groups for both donor and patient samples, which is particularly interesting in the second case, due to the strong difference between donor and patient samples in the number of recruited individuals for both age-groups. These data agree with the fact that DPP-IV activities did not differ significantly with age (Hino et al, 1975).…”

Section: Scd26 Levels In Serum Of Healthy Donors and Patients With Cosupporting

confidence: 91%

See 1 more Smart Citation

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

et al. 2000

View full text Add to dashboard Cite

CD26 is an ectoenzyme with dipeptidyl peptidase IV activity expressed on a variety of cell types. Although the function of the high concentration of serum-soluble CD26 (sCD26) is unknown, it may be related to the cleavage of biologically active polypeptides. As CD26 or enzymatic activity levels were previously associated with cancer, we examined the potential diagnostic and prognostic value of preoperative sCD26 measurements by ELISA in colorectal carcinoma patients. We found a highly significant difference between sCD26 levels in healthy donors (mean 559.7 ± 125.5 μg l –1 ) and cancer patients (mean 261.7 ± 138.1 μg l –1 ) ( P < 0.001). A cut-off at 410 μg l –1 gave 90% sensitivity with 90% specificity which means that the diagnostic efficiency of sCD26 is higher than that shown by other markers, particularly in patients at early stages. Moreover, sCD26 as a variable is not related with Dukes’ stage classification, age, gender, tumour location or degree of differentiation. With a follow-up of 2 years until recurrence, preliminary data show that sCD26 can be managed as a prognostic variable of early carcinoma patients. In addition, the origin of sCD26 is discussed. © 2000 Cancer Research Campaign

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Scd26 Levels In Serum Of Healthy Donors and Patients With Cosupporting

confidence: 91%

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

et al. 2000

View full text Add to dashboard Cite

show abstract

“…DP IV occurs widely in mammalian tissues such as liver, kidney, small intestine, salivary gland, blood cells and plasma; however, little is known about the physiological role of ihis enzyme [1,2]. Among blood celts.…”

Section: Introductionmentioning

confidence: 99%

Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lprmice correlates with disease onset

Iizuka

Bachovchin

Stollar

1994

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARY DP IV (CD26), a serine protease expressed on activated T cells, participates in immune responses in vivo as well as in vitro. We measured cell surface and serum DP IV in mice of the autoimmune MRL/Mp‐lpr/lpr (MRL/1) strain, which is characterized by massive T cell proliferation and production of anti‐nuclear autoantibodies. The mass of inguinal lymph nodes correlated with scrum DP IV activity. Furthermore, serum DP IV activity increased markedly in parallel with the acceleration of lymph node swelling and anti‐nDNA antibody production. Serum DP IV activity in 16‐week‐old MRL/I mice reached levels up to three times higher than those in age‐matched MRL/Mp‐+/+ mice or BALB/c mice. Immunohistochemical staining and flow cytometric analysis identified DV IV on surfaces of lymphocytes from the enlarged lymph nodes of MRL/1 mice. Subcutaneous injection of the mechanism‐based inhibitor, Pro‐boroPro, reduced protease activity in serum and cell suspensions prepared from spleen and lymph nodes, confirming the identity of the enzyme as DP IV. These results indicate that the massively accumulating lymphocytes of MRL/1 mice have a property characteristic of activated T cells, although they express little surface CD4 or CD8 and do not produce IL‐2. DP IV may participate in the role these cells play in the pathogenesis of MRL/1 autoimmune disease.

show abstract

“…1989), lymphocyte activation (Schon et al, 1987) and interactions with the extracellular matrix (Hanski et al, 1988). Also, a number of clinical studies have shown that DPP-IV levels may be altered in cultured human cancer cells (Komatsu et al, 1987) and in the serum of cancer patients (Hino et al, 1975;Kojima et al, 1979). MATERIAL …”

mentioning

confidence: 99%

Expression of dipeptidyl aminopeptidase IV during enterocytic differentiation of human colon cancer (Caco‐2) cells

Yoshioka

Erickson

Matsumoto

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

The human colon cancer cell line Caco-2 spontaneously differentiates to an enterocyte-like cell after confluence under standard culture conditions. This is characterized by polarization of the cell monolayer with the appearance of tight junctions, a brush border membrane and expression of brush-border-membrane-associated hydrolases. Studies have shown that differentiated Caco-2 cells express relatively high levels of dipeptidyl aminopeptidase IV (DPP IV) when compared with other enzymes. However, the biochemical mechanisms involved in the expression of DPP IV in differentiated cells are currently unknown. Therefore, the biosynthesis and expression of membrane-associated DPP IV in undifferentiated (0 day confluent) and differentiated (14 day confluent) Caco-2 cells were examined. Though levels of DPP IV activity in differentiated cells was 5- to 6-fold higher than undifferentiated cells, there was only a 1.6-fold difference in the synthetic rate. Post-translational processing of newly synthesized DPP IV occurred at a slower rate in differentiated cells, though there were no major differences in the type or degree of glycosylation. A comparison of the degradation rates revealed that they were similar with a half-life of approximately 8 to 10 days. We conclude that the high levels of DPP IV expressed in differentiated Caco-2 cells is primarily due to an increase in enzyme synthesis. In addition, accumulation of the enzyme is aided by its slow turnover rate.

show abstract

glycylprolyl β-naphthylamidase activity in human serum

Cited by 72 publications

References 14 publications

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lprmice correlates with disease onset

Expression of dipeptidyl aminopeptidase IV during enterocytic differentiation of human colon cancer (Caco‐2) cells

Contact Info

Product

Resources

About